CG Oncology (NASDAQ: CGON) and the Society of Urologic Oncology Clinical Trials Consortium announced recipients of the second annual NMIBC Research Fellowship, supporting Non-Muscle Invasive Bladder Cancer research with grants up to $50,000 each.
Grants were awarded to Dr. Patrick Hensley and Dr. Daniel Joyce for projects in AI prognostic biomarkers and price transparency.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – CGON
+0.59%
1 alert
+0.59%Session close to close
$5.82BMarket Cap
0.0xRel. Volume
In the May 19 session, CGON gained 0.59%, reflecting a mild positive market reaction.
This announcement highlights CG Oncology’s continued commitment to Non‑Muscle Invasive Bladder Cance...
Analysis
This announcement highlights CG Oncology’s continued commitment to Non‑Muscle Invasive Bladder Cancer through its CG‑SUO‑CTC fellowship, providing grants up to $50,000.00 to early-career investigators. It complements recent AUA 2026 presentations and positive CORE‑008 Phase 2 data, reinforcing the company’s academic and clinical footprint in NMIBC. Investors may watch for how such collaborations support cretostimogene development, future regulatory milestones, and any updates in SEC filings or insider activity that could affect the company’s strategic flexibility.
Key Figures
Research fellowship grant:up to $50,000.00
1 metrics
Research fellowship grantup to $50,000.00Per-recipient NMIBC research fellowship support
Year‑end 2025 results with strong cash and clear 1H 2026 clinical milestones.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent CGON news often produced modest reactions, with positive clinical or financial updates sometimes followed by selloffs, indicating occasional divergence between favorable headlines and short-term price moves.
Recent Company History
Over the last few months, CG Oncology has reported multiple milestones. On Feb 27, year-end 2025 results highlighted $903.0M in cash and key 1H 2026 clinical readouts. Q1 2026 results on May 8 showed continued investment and over $1.0B in cash. The company then announced investor conference participation and AUA 2026 presentations, including positive CORE‑008 Cohort CX Phase 2 data on May 15. Today’s fellowship announcement extends that AUA-aligned research and NMIBC focus rather than adding new pivotal clinical or financial data.
"commitment to improving the understanding and treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)."
A form of bladder cancer that is confined to the inner lining of the bladder and has not grown into the deeper muscle layer; think of it like a stain on wallpaper rather than damage to the wall’s studs. It matters to investors because it has different treatment, monitoring and recurrence patterns than deeper cancers, driving demand for repeated outpatient procedures, local therapies and diagnostic tests that affect revenue, trial design and pricing dynamics in healthcare markets.
nmibcmedical
"treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). They include:"
A common form of bladder cancer that stays confined to the bladder’s inner lining or the layer just below it and has not grown into the deeper muscle wall. It matters to investors because it often requires repeated procedures, ongoing surveillance and long-term treatments, creating a sizable and stable market for diagnostics, drugs and medical devices; think of it like a surface-level problem that needs frequent check-ups and follow-up care rather than a one-time fix.
artificial intelligencetechnical
"Development of an artificial intelligence powered prognostic biomarker for intravesical cretostimogene"
Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.
prognostic biomarkermedical
"artificial intelligence powered prognostic biomarker for intravesical cretostimogene"
A prognostic biomarker is a measurable sign—like a molecule, gene pattern or lab result—that helps predict how a disease will progress over time regardless of which treatment is used. For investors, prognostic biomarkers matter because they can clarify the likely size and urgency of a patient group, shape clinical trial design and regulatory discussions, and therefore affect how a therapy or diagnostic is valued and adopted; think of it as a weather forecast for a disease that helps companies plan and investors price risk.
intravesicalmedical
"prognostic biomarker for intravesical cretostimogene in BCG unresponsive non-muscle invasive bladder cancer"
Intravesical describes a medical treatment or procedure where a drug or therapy is placed directly into the bladder through a catheter rather than taken by mouth or injected into the bloodstream. For investors, it signals a focused delivery method that can increase local effectiveness and reduce whole‑body side effects, often affecting a product’s clinical value, patient convenience, regulatory path, and market niche — like watering a plant at its roots instead of spraying its leaves.
bcg-unresponsivemedical
"cretostimogene in BCG unresponsive non-muscle invasive bladder cancer"
BCG-unresponsive describes a situation in which a patient’s bladder cancer does not shrink or returns despite receiving an adequate course of BCG, a common vaccine-based intravesical treatment used to stimulate the immune system in the bladder. For investors this matters because it defines a group of patients who need alternative therapies or procedures, shaping clinical trial eligibility, regulatory pathways, and the potential market for new drugs; think of it like weeds that resist the usual weed killer and require a different product.
spatial transcriptomic profilingmedical
"Spatial transcriptomic profiling of the tumor microenvironment in BCG-unresponsive NMIBC patients"
Spatial transcriptomic profiling maps which genes are active and where they are located within a tissue sample, combining gene activity measurements with their physical position much like a weather map shows temperatures across a city. Investors care because this method helps drug developers and diagnostics companies identify precise disease targets and biomarkers, which can speed up R&D, improve success rates, and create more valuable, differentiated products.
intra-tumor heterogeneitymedical
"Dynamic intra-tumor heterogeneity in non-muscle invasive bladder cancer"
Intra-tumor heterogeneity is the existence of different types of cells within a single tumor that can vary in their genetics, behavior, and response to treatment. For investors, this matters because a drug or diagnostic that works on one cell type may fail against others, increasing development risk and uncertainty about clinical success; think of it like trying to treat a garden with weeds and flowers that need different care.
Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC
Last year’s awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA
SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the recipients of the second annual CG-SUO-CTC NMIBC Research Fellowship designed to support the development of outstanding clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). They include:
Patrick Hensley, MD, University of Kentucky Research Foundation Development of an artificial intelligence powered prognostic biomarker for intravesical cretostimogene in BCG unresponsive non-muscle invasive bladder cancer
Daniel Joyce, MD, MS,Vanderbilt University Medical Center Providing individualized price transparency at the point of care for patients with BCG-unresponsive non-muscle-invasive bladder cancer
Additionally, the 2025 NMIBC Research Fellowship grant recipients presented their research at the SUO 2026 Annual Meeting at the AUA. The details of their presentations are as follows:
Taylor A. Goodstein, MD, Emory University Spatial transcriptomic profiling of the tumor microenvironment in BCG-unresponsive NMIBC patients treated with novel intravesical gene therapies
Saum B. Ghodoussipour, MD,Rutgers Cancer Institute of New Jersey Dynamic intra-tumor heterogeneity in non-muscle invasive bladder cancer
“Partnering with the SUO-CTC on this fellowship reflects our shared commitment to advancing care for patients with bladder cancer,” said Ambaw Bellete, President & Chief Operating Officer, CG Oncology. “By supporting innovative research and fostering collaboration, this program helps accelerate progress toward meaningful breakthroughs that can make a lasting difference for patients.”
Drs. Goodstein and Ghodoussipour shared reflections on the impact of the fellowship:
“This fellowship was instrumental in advancing my work. It gave me the opportunity to collaborate with an outstanding mentor and share our research at AUA. It strengthened my commitment to improving understanding and care for patients with NMIBC,” said Dr. Goodstein.
Dr. Ghodoussipour added, “Receiving this fellowship allowed me to explore critical scientific questions in NMIBC early in my career. The support and mentorship were invaluable, and presenting at AUA was a meaningful milestone. It reinforced my dedication to advancing research that can improve patient outcomes.”
About The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC) SUO-CTC is a clinical research investigator network of over 750 members from more than 350 clinical sites in the U.S. and Canada. This national alliance of leading academic and community based uro-oncologists is committed to furthering urology research. The SUO-CTC is a registered 501c3 not-for-profit corporation and has a cooperative relationship with the Society of Urologic Oncology (SUO). To learn more please visit: https://suoctc.org/
About CG Oncology CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Contacts: Media Sarah Connors Vice President, Communications and Patient Advocacy, CG Oncology sarah.connors@cgoncology.com
SUO-CTC Pam Murphy Executive Director, Clinical Research Services pam@wjweiser.com
FAQ
What is the CG Oncology (NASDAQ: CGON) and SUO-CTC NMIBC Research Fellowship?
The NMIBC Research Fellowship is a joint program supporting clinical research in Non-Muscle Invasive Bladder Cancer. According to CG Oncology, it funds early-career investigators to advance understanding and treatment of NMIBC through competitive research grants and mentorship-focused projects.
Who received the 2026 NMIBC Research Fellowship awards supported by CG Oncology (CGON)?
The 2026 NMIBC Research Fellowship awards went to Dr. Patrick Hensley and Dr. Daniel Joyce. According to CG Oncology, each award provides up to $50,000 to support projects focused on AI-powered prognostic biomarkers and individualized price transparency for BCG-unresponsive NMIBC.
How much funding does each CG Oncology (CGON) NMIBC Research Fellowship provide?
Each NMIBC Research Fellowship provides up to $50,000 in grant funding. According to CG Oncology, this financial support is intended to help early-career investigators conduct impactful NMIBC research, including innovative approaches such as AI biomarkers and cost transparency at the point of care.
What research projects are funded by the 2026 CGON NMIBC Research Fellowship awards?
The 2026 fellowship funds an AI-powered prognostic biomarker for intravesical cretostimogene and individualized price transparency tools. According to CG Oncology, both projects target patients with BCG-unresponsive non-muscle invasive bladder cancer, aiming to improve clinical decision-making and patient care.
Which 2025 NMIBC Research Fellowship recipients presented at the SUO 2026 Annual Meeting?
2025 fellowship recipients Dr. Taylor A. Goodstein and Dr. Saum B. Ghodoussipour presented at the SUO 2026 Annual Meeting. According to CG Oncology, their work covered spatial transcriptomic profiling and dynamic intra-tumor heterogeneity in BCG-unresponsive non-muscle invasive bladder cancer.
How does the CG Oncology (CGON) NMIBC fellowship support early-career cancer researchers?
The fellowship supports early-career researchers through funding, mentorship, and presentation opportunities. According to CG Oncology, recipients highlighted that the program enabled exploration of key NMIBC questions, collaboration with mentors, and sharing results at AUA meetings, reinforcing commitment to bladder cancer research.
